• 1. PET imaging with multimodal upconversion nanoparticles
  Juan Gallo,Israt S. Alam,Jiefu Jin,Yan-Juan Gu,Eric O. Aboagye,Wing-Tak Wong,Nicholas J. Long Dalton Trans. 2014 43 5535
• 2. Microfluidic perfusion systems for secretion fingerprint analysis of pancreatic islets: applications, challenges and opportunities
  F. Rafael Castiello,Khalil Heileman,Maryam Tabrizian Lab Chip 2016 16 409
• 3. Microfluidic perfusion systems for secretion fingerprint analysis of pancreatic islets: applications, challenges and opportunities
  F. Rafael Castiello,Khalil Heileman,Maryam Tabrizian Lab Chip 2016 16 409
• 4. Wheat germ agglutinin modification of lipid–polymer hybrid nanoparticles: enhanced cellular uptake and bioadhesion
  Ying Liu,Yiqing Zhao,Jinguang Liu,Meiying Zhang,Minglei Yu,Nianping Feng RSC Adv. 2016 6 36125
• 5. Peptide modified gold nanoparticles for improved cellular uptake, nuclear transport, and intracellular retention
  C. Yang,J. Uertz,D. Yohan,B. D. Chithrani Nanoscale 2014 6 12026

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Acylaminobenzoic acid and derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Acylaminobenzoic acid and derivatives

Introduction to 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid (CAS No. 17057-07-7)

3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid, also known by its CAS number 17057-07-7, is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrrole derivatives and is characterized by its unique structural features, which include a benzoic acid moiety and a 2,5-dioxopyrrole ring. These structural elements contribute to its diverse biological activities and potential therapeutic applications.

The molecular formula of 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid is C₁₁H₈N₂O₄, and it has a molecular weight of approximately 236.19 g/mol. The compound is a white crystalline solid at room temperature and is soluble in polar solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF). Its solubility in water is limited, which can be a consideration in its formulation for various applications.

In recent years, 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid has been extensively studied for its potential as a lead compound in drug discovery. One of the key areas of interest is its anti-inflammatory properties. Research has shown that this compound can effectively inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These findings suggest that 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid could be a valuable candidate for the development of new anti-inflammatory drugs.

Beyond its anti-inflammatory effects, 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid has also been investigated for its potential anticancer properties. Studies have demonstrated that this compound can induce apoptosis in various cancer cell lines, including those derived from breast cancer and colon cancer. The mechanism of action appears to involve the modulation of signaling pathways such as the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. These pathways are crucial for cell survival and proliferation, and their inhibition by 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid suggests its potential as an anticancer agent.

The structural features of 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid have also been explored for their ability to enhance drug delivery systems. The presence of the benzoic acid moiety allows for the formation of ester prodrugs that can improve the solubility and bioavailability of the compound. This is particularly important for oral administration and can enhance the therapeutic efficacy while reducing side effects.

In addition to its direct biological activities, 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid has been used as a building block in the synthesis of more complex molecules with enhanced pharmacological properties. For example, researchers have synthesized derivatives with additional functional groups such as amino acids or sugars to create compounds with improved selectivity and potency. These derivatives have shown promise in preclinical studies and are currently being evaluated for their potential therapeutic applications.

The safety profile of 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-y l)benzoic acid is another important aspect that has been investigated. Toxicological studies have shown that this compound exhibits low toxicity at therapeutic concentrations. However, like any chemical compound used in pharmaceutical research, it is essential to conduct thorough safety assessments to ensure its suitability for clinical use.

In conclusion, 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol - 1 - yl)benzoic acid (CAS No. 17057 - 07 - 7) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique structural features make it an attractive candidate for further research and development in areas such as anti-inflammatory drugs and anticancer agents. As ongoing studies continue to uncover new insights into its mechanisms of action and safety profile, this compound holds significant promise for contributing to advancements in medicinal chemistry and pharmaceutical science.

• 17057-04-4(4-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)